VYNE Therapeutics Inc.VYNENASDAQ
Loading
Free Cash Flow Growth AcceleratingAccelerating
Percentile Rank95
3Y CAGR+1.0%
Year-over-Year Change
Year-over-year free cash flow growth rate
3Y CAGR
+1.0%/yr
Quarterly compound
Percentile
P95
Near historical high
vs 3Y Ago
1x
Modest growth
Streak
3 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 46.96% |
| Q3 2025 | 34.31% |
| Q2 2025 | 5.74% |
| Q1 2025 | -25.72% |
| Q4 2024 | -7.12% |
| Q3 2024 | -0.33% |
| Q2 2024 | -6.28% |
| Q1 2024 | -55.36% |
| Q4 2023 | 0.29% |
| Q3 2023 | 46.19% |
| Q2 2023 | -74.77% |
| Q1 2023 | -41.37% |
| Q4 2022 | 45.61% |
| Q3 2022 | 13.37% |
| Q2 2022 | 9.01% |
| Q1 2022 | 9.77% |
| Q4 2021 | 42.89% |
| Q3 2021 | -7.90% |
| Q2 2021 | -29.53% |
| Q1 2021 | 50.76% |
| Q4 2020 | -7.83% |
| Q3 2020 | 34.21% |
| Q2 2020 | 31.24% |
| Q1 2020 | -218.36% |
| Q4 2019 | -0.21% |
| Q3 2019 | -14.96% |
| Q2 2019 | 21.18% |
| Q1 2019 | -8.63% |
| Q4 2018 | -35.39% |
| Q3 2018 | 2.88% |
| Q2 2018 | -12.08% |
| Q1 2018 | -10.63% |
| Q4 2017 | 18.41% |
| Q3 2017 | -33902.70% |
| Q2 2017 | 100.66% |
| Q1 2017 | -22.56% |
| Q4 2016 | 0.00% |
| Q3 2016 | 0.00% |